Isomorphic Labs valuation, funding and investors
Isomorphic Labs works in AI-Driven drug discovery services, based in London, United Kingdom. Founded in 2021, it has about 432 employees.
- Last round
- Series B · $2.10B · May 2026
- Valuation at last round
- $12.48B · implied
- Headcount
- 432 · growing
- Grade
- B
- Founded
- 2021
Isomorphic Labs valuation today
VCMC values Isomorphic Labs at $15.2B today, with a range of $9.1B to $27.4B and a grade of B. The valuation starts from its last funding round, a Series B round in May 2026.
Valuation by date (72 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2021 | $10.7M | $3.89M – $29.3M | $11.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $10.8M | $3.93M – $29.6M | $12.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $10.9M | $3.96M – $29.9M | $12.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $11.0M | $3.99M – $30.1M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $11.1M | $4.03M – $30.4M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $11.2M | $4.07M – $30.7M | $12.3M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $11.3M | $4.10M – $31.0M | $12.4M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $11.4M | $4.14M – $31.2M | $12.5M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $11.5M | $4.18M – $31.5M | $12.6M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $11.6M | $4.22M – $31.8M | $12.7M (+10%) | before first round | – | unknown | D | 0% |
| 1 Nov 2021 | $11.7M | $4.25M – $32.1M | $12.8M (+10%) | before first round | – | unknown | D | 0% |
| 1 Dec 2021 | $11.8M | $4.29M – $32.4M | $12.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2022 | $11.9M | $4.33M – $32.7M | $13.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $12.0M | $4.36M – $32.9M | $13.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2022 | $12.1M | $4.39M – $33.2M | $13.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2022 | $12.2M | $4.43M – $33.4M | $13.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2022 | $12.2M | $4.46M – $33.6M | $13.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2022 | $12.3M | $4.49M – $33.9M | $13.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2022 | $12.4M | $4.53M – $34.1M | $13.6M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2022 | $12.5M | $4.56M – $34.4M | $13.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Sep 2022 | $12.6M | $4.59M – $34.7M | $13.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Oct 2022 | $12.7M | $4.63M – $34.9M | $13.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Nov 2022 | $12.8M | $4.66M – $35.2M | $14.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Dec 2022 | $12.9M | $4.70M – $35.4M | $14.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2023 | $13.0M | $4.73M – $35.7M | $14.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2023 | $13.1M | $4.77M – $36.0M | $14.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2023 | $13.2M | $4.80M – $36.2M | $14.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2023 | $16.6M | $6.06M – $45.7M | $18.2M (+9%) | before first round | 65 | unknown | D | 0% |
| 1 May 2023 | $16.8M | $6.10M – $46.0M | $18.3M (+9%) | before first round | 65 | unknown | D | 0% |
| 1 Jun 2023 | $16.9M | $6.15M – $46.4M | $18.4M (+9%) | before first round | 65 | unknown | D | 0% |
| 1 Jul 2023 | $17.0M | $6.19M – $46.7M | $18.6M (+9%) | before first round | 65 | unknown | D | 0% |
| 1 Aug 2023 | $17.1M | $6.24M – $47.1M | $18.6M (+8%) | before first round | 65 | unknown | D | 0% |
| 1 Sep 2023 | $17.3M | $6.29M – $47.4M | $18.6M (+8%) | before first round | 65 | unknown | D | 0% |
| 1 Oct 2023 | $21.8M | $7.17M – $48.9M | $23.3M (+7%) | before first round | 75 | up | C | 0% |
| 1 Nov 2023 | $22.0M | $7.23M – $49.3M | $23.3M (+6%) | before first round | 75 | up | C | 0% |
| 1 Dec 2023 | $22.1M | $7.28M – $49.6M | $23.3M (+5%) | before first round | 75 | up | C | 0% |
| 1 Jan 2024 | $22.3M | $7.33M – $50.0M | $23.3M (+5%) | before first round | 75 | up | C | 0% |
| 1 Feb 2024 | $22.5M | $7.39M – $50.4M | $23.3M (+4%) | before first round | 75 | up | C | 0% |
| 1 Mar 2024 | $27.2M | $11.6M – $54.0M | $28.0M (+3%) | before first round | 110 | growing | C | 0% |
| 1 Apr 2024 | $27.4M | $11.7M – $54.4M | $28.0M (+2%) | before first round | 110 | growing | C | 0% |
| 1 May 2024 | $27.6M | $11.8M – $54.8M | $28.0M (+1%) | before first round | 110 | growing | C | 0% |
| 1 Jun 2024 | $27.8M | $11.9M – $55.2M | $28.0M (+1%) | before first round | 110 | growing | C | 0% |
| 1 Jul 2024 | $28.0M | $12.0M – $55.6M | $28.0M (0%) | before first round | 110 | growing | C | 0% |
| 1 Aug 2024 | $29.1M | $12.5M – $57.8M | $29.1M (0%) | before first round | 140 | growing | C | 0% |
| 1 Sep 2024 | $29.1M | $12.5M – $57.8M | $29.1M (0%) | before first round | 140 | growing | C | 0% |
| 1 Oct 2024 | $29.1M | $12.5M – $57.8M | $29.1M (0%) | before first round | 140 | growing | C | 0% |
| 1 Nov 2024 | $29.7M | $12.7M – $59.0M | $29.7M (0%) | before first round | 160 | growing | C | 0% |
| 1 Dec 2024 | $29.7M | $12.7M – $59.0M | $29.7M (0%) | before first round | 160 | growing | C | 0% |
| 1 Jan 2025 | $30.3M | $13.0M – $60.2M | $30.3M (0%) | before first round | 180 | growing | C | 0% |
| 1 Feb 2025 | $30.3M | $13.0M – $60.2M | $30.3M (0%) | before first round | 180 | growing | C | 0% |
| 1 Mar 2025 | $30.3M | $13.0M – $60.2M | $30.3M (0%) | before first round | 180 | growing | C | 0% |
| 1 Apr 2025 | $6.1B | $4.0B – $10.2B | $6.7B (+10%) | after a round | 180 | growing | B | 0% |
| 1 May 2025 | $6.2B | $4.0B – $10.2B | $6.7B (+9%) | after a round | 180 | growing | B | 0% |
| 1 Jun 2025 | $6.2B | $4.0B – $10.2B | $6.7B (+8%) | after a round | 180 | growing | B | 0% |
| 1 Jul 2025 | $6.3B | $4.0B – $10.2B | $6.7B (+7%) | after a round | 180 | growing | B | 0% |
| 1 Aug 2025 | $6.5B | $4.2B – $11.0B | $7.2B (+12%) | after a round | 247 | growing | B | 0% |
| 1 Sep 2025 | $6.6B | $4.3B – $11.0B | $7.2B (+10%) | after a round | 247 | growing | B | 0% |
| 1 Oct 2025 | $6.6B | $4.3B – $11.0B | $7.2B (+9%) | after a round | 247 | growing | B | 0% |
| 1 Nov 2025 | $6.7B | $4.3B – $11.0B | $7.2B (+7%) | after a round | 247 | growing | B | 0% |
| 1 Dec 2025 | $7.0B | $4.5B – $11.5B | $7.6B (+7%) | after a round | 304 | growing | B | 0% |
| 1 Jan 2026 | $7.2B | $4.5B – $11.6B | $7.6B (+6%) | after a round | 316 | growing | B | 0% |
| 1 Feb 2026 | $7.4B | $4.5B – $11.6B | $7.6B (+4%) | after a round | 316 | growing | B | 0% |
| 1 Mar 2026 | $7.5B | $4.5B – $11.6B | $7.6B (+2%) | after a round | 316 | growing | B | 0% |
| 1 Apr 2026 | $7.6B | $4.5B – $11.6B | $7.6B (0%) | after a round | 316 | growing | B | 0% |
| 1 May 2026 | $7.9B | $4.7B – $12.1B | $7.9B (0%) | after a round | 378 | growing | B | 0% |
| 13 May 2026 | $12.5B | $8.8B – $26.6B | $18.7B (+50%) | after a round | 378 | growing | B | 0% |
| 1 Jun 2026 | $12.8B | $8.8B – $26.6B | $18.7B (+47%) | after a round | 378 | growing | B | 0% |
| 1 Jul 2026 | $13.2B | $8.8B – $26.6B | $18.7B (+42%) | after a round | 378 | growing | B | 0% |
| 1 Aug 2026 | $13.7B | $8.9B – $26.9B | $19.0B (+39%) | after a round | 403 | growing | B | 0% |
| 1 Sep 2026 | $14.2B | $9.0B – $27.3B | $19.2B (+35%) | after a round | 426 | growing | B | 0% |
| 1 Oct 2026 | $14.8B | $9.1B – $27.4B | $19.3B (+30%) | after a round | 432 | growing | B | 0% |
| 24 Oct 2026 | $15.2B | $9.1B – $27.4B | $19.3B (+27%) | after a round | 432 | growing | B | 0% |
Key facts about Isomorphic Labs
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- about 432 +75% in a year
- Total raised
- $2.70B
- Funding rounds
- 2
- Last round
- Series B May 2026
Isomorphic Labs was founded in 2021 by Demis Hassabis.
Isomorphic Labs funding history
Isomorphic Labs has 2 funding rounds on record, from Mar 2025 to May 2026, $2.70B in total. None disclosed a valuation.
Series B 12 May 2026
Led by Thrive Capital; with Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund.
Sources: techfundingnews.com, isomorphiclabs.com, isomorphiclabs.com and 1 more
$2.10B
Growth Equity 31 Mar 2025
Led by Thrive Capital; with GV, Alphabet.
Sources: techfundingnews.com, isomorphiclabs.com, bioindustry.org and 6 more
$600M
Isomorphic Labs investors
7 investors have backed Isomorphic Labs; Thrive Capital led at least one round.
- Thrive Capital lead, 2 rounds
- Alphabet 2 rounds
- GV 2 rounds
- CapitalG
- Temasek
- UK Sovereign AI Fund
What Isomorphic Labs does
Isomorphic Labs works in biotechnology, with 13 recorded offerings and customers in healthcare and pharmaceuticals.
Isomorphic Labs Limited is a British company engaged in drug discovery and AI-driven drug design. The company develops proprietary AI technologies and a unified drug design engine to support scientific discovery and drug development for pharmaceutical companies, biotechnology firms, and clinical research organizations. Isomorphic Labs also operates as a provider of in-silico experimentation infrastructure, utilizing a dataverse and GPU fleets to facilitate computational drug design.
Description from Veridion's company data.
Products and services
- AI-Driven Drug Discovery Services
- Unified Drug Design Engine Development
- In-Silico Experimentation Services
- Drug Candidate Generation and Evaluation
- Scientific Insight Acceleration Solutions
- Pharmaceutical Partnership Development Services
- Clinical Research Collaboration Services
- Ethical AI Consulting Services
- Sustainable Technology Development Services
- Advanced Machine Learning Model Development
- Biological Data Integration Services
- Proprietary Dataverse Management Services
- GPU-Based Computing Services
Markets
- Healthcare
- Pharmaceuticals
Technology
- AI-Driven Drug Design
- Unified Drug Design Engine
- In-Silico Experimentation Infrastructure
Certifications
- GDPR compliant
Business model
- Business-to-Business
- Software-as-a-Service
- Enterprise
Industry codes (NAICS)
- 541511 Custom Computer Programming Services 60% match
- 541690 Other Scientific and Technical Consulting Services 40% match
Questions about Isomorphic Labs
What is Isomorphic Labs worth?
Valuation $15.2B (range $9.1B to $27.4B), as of 24 Oct 2026.
Has Isomorphic Labs raised money?
Isomorphic Labs has 2 funding rounds on record, from Mar 2025 to May 2026, $2.70B in total. None disclosed a valuation.
Who has invested in Isomorphic Labs?
Thrive Capital, Alphabet, GV, CapitalG, MGX and Temasek, and 1 more. Lead investors include Thrive Capital.
How many people work at Isomorphic Labs?
About 432, up 75% over the last year. Headcount grew from 65 in Apr 2023 to 432 in Sep 2026.
What does Isomorphic Labs do?
Isomorphic Labs works in biotechnology, with 13 recorded offerings and customers in healthcare and pharmaceuticals. Its main offerings are AI-Driven drug discovery services, unified drug design engine development and in-silico experimentation services.
When was Isomorphic Labs founded, and where is it based?
Isomorphic Labs was founded in 2021 and is based in London, United Kingdom. It has about 432 employees, up 75% over the last year.